AbbVie Pounces On Chance To Buy Revenues In $63bn Mega-Deal For Allergan

AbbVie will gain the $3.58bn Botox business, a women's health franchise and gastrointestinal products in an opportunistic acquisition intended to reduce the company's dependence on Humira.